

Jordi Colmenero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/490384/publications.pdf>

Version: 2024-02-01

82
papers

4,904
citations

147801

31
h-index

91884

69
g-index

86
all docs

86
docs citations

86
times ranked

6710
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary herpes simplex virus type 1 infection with acute liver failure in solid organ transplantation: Report of three cases and review. <i>IDCases</i> , 2022, 28, e01485.	0.9	4
2	Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplantation. <i>Liver Transplantation</i> , 2022, 28, 1332-1344.	2.4	4
3	Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study. <i>Liver Transplantation</i> , 2022, 28, 1257-1261.	2.4	2
4	Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 1671-1682.	4.7	31
5	De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management—Guidelines From the ILTS-SETH Consensus Conference. <i>Transplantation</i> , 2022, 106, e30-e45.	1.0	29
6	The Role of Arterial Stiffness in the Estimation of Cardiovascular Risk in Liver Transplant Recipients. <i>Transplantation Direct</i> , 2022, 8, e1272.	1.6	4
7	The ILTS-SETH Consensus Conference on Extrahepatic Cancer and Liver Transplantation: Paving the Way. <i>Transplantation</i> , 2022, 106, e1-e2.	1.0	2
8	Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. <i>Journal of Hepatology</i> , 2021, 74, 148-155.	3.7	261
9	Liver Transplantation for Acute Intermittent Porphyria. <i>Liver Transplantation</i> , 2021, 27, 491-501.	2.4	32
10	Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study. <i>Gastroenterology</i> , 2021, 160, 1151-1163.e3.	1.3	130
11	Modulating immunosuppression in liver transplant patients with COVID-19. <i>Gut</i> , 2021, 70, 1412-1414.	12.1	16
12	Expanding Indications of Liver Transplantation in Spain: Consensus Statement and Recommendations by the Spanish Society of Liver Transplantation. <i>Transplantation</i> , 2021, 105, 602-607.	1.0	24
13	A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. <i>PLoS ONE</i> , 2021, 16, e0247251.	2.5	38
14	Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. <i>American Journal of Transplantation</i> , 2021, 21, 2876-2884.	4.7	32
15	Reply to: “Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients” <i>Journal of Hepatology</i> , 2021, 75, 228-229.	3.7	0
16	Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3971-3979.	4.7	85
17	Is antivitamin K reversal required in patients with cirrhosis undergoing liver transplantation?. <i>Transfusion</i> , 2021, 61, 3008-3016.	1.6	4
18	A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. <i>Journal of Hepatology</i> , 2021, 75, 275-283.	3.7	23

#	ARTICLE	IF	CITATIONS
19	Combined Heart and Liver Transplantation for Uhl's Anomaly: A Case Report. <i>Transplantation Proceedings</i> , 2021, 53, 2751-2753.	0.6	0
20	Trasplante hepático y renal en la enfermedad poliquística hepatorrenal. <i>Gastroenterología Y Hepatología</i> , 2021, 44, 552-558.	0.5	1
21	Organ Donation and Transplantation During the COVID-19 Pandemic: A Summary of the Spanish Experience. <i>Transplantation</i> , 2021, 105, 29-36.	1.0	49
22	New technologies applied to master education in the time of COVID-19. <i>Korean Journal of Transplantation</i> , 2021, 35, S28-S28.	0.1	0
23	Liver transplant with controlled donors after circulatory death with normothermic regional perfusion and brain dead donors: A multicenter cohort study of transfusion, one-year graft survival and mortality. <i>International Journal of Surgery</i> , 2021, 96, 106169.	2.7	5
24	Incidence, Predictors, and Impact on Survival of Long-term Cardiovascular Events After Liver Transplantation. <i>Transplantation</i> , 2020, 104, 317-325.	1.0	14
25	Increased incidence of COVID-19 among liver transplant patients in Europe. <i>Transplant International</i> , 2020, 33, 1823-1824.	1.6	1
26	Active Smoking Before Liver Transplantation in Patients with Alcohol Use Disorder: Risk Factors and Outcomes. <i>Journal of Clinical Medicine</i> , 2020, 9, 2710.	2.4	4
27	MicroRNAs 155p, 122p, and 181a Identify Patients With Graft Dysfunction Due to T Cell-Mediated Rejection After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1275-1286.	2.4	8
28	Kidney Graft Outcomes in High Immunological Risk Simultaneous Liver-Kidney Transplants. <i>Liver Transplantation</i> , 2020, 26, 517-527.	2.4	11
29	Profilaxis y tratamiento de la infección por virus de la hepatitis B en el trasplante hepático. VII Documento de consenso de la Sociedad Española de Trasplante Hepático. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 169-177.	0.5	2
30	Donor-specific antibodies in liver transplantation. <i>Gastroenterología Y Hepatología</i> , 2020, 43, 34-45.	0.5	19
31	Donation after circulatory death liver transplantation: consensus statements from the Spanish Liver Transplantation Society. <i>Transplant International</i> , 2020, 33, 902-916.	1.6	28
32	Letter: unknown denominator and misleading conclusions in COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1241-1242.	3.7	1
33	Fanconi syndrome due to tenofovir disoproxil fumarate (TDF) after liver transplantation. <i>Digestive and Liver Disease</i> , 2019, 51, 1352-1353.	0.9	4
34	Prediction of Alcohol Relapse Among Liver Transplant Candidates With Less Than 6 Months of Abstinence Using the High-Risk Alcoholism Relapse Score. <i>Liver Transplantation</i> , 2019, 25, 1142-1154.	2.4	20
35	Torque Teno Virus Is Associated With the State of Immune Suppression Early After Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 302-310.	2.4	38
36	Endoscopic management of bile leaks after liver transplantation: An analysis of two high-volume transplant centers. <i>United European Gastroenterology Journal</i> , 2018, 6, 89-96.	3.8	15

#	ARTICLE	IF	CITATIONS
37	Venous Thrombotic Events After Liver Transplantation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 317-322.	1.7	8
38	Mannose-Binding Lectin-Deficient Donors Increase the Risk of Bacterial Infection and Bacterial Infection-Related Mortality After Liver Transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 197-206.	4.7	13
39	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. <i>Hepatology</i> , 2018, 67, 1683-1694.	7.3	114
40	Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). <i>Liver Transplantation</i> , 2018, 24, 369-379.	2.4	47
41	Modularity and Blended Methodology on Master Education for Donation and Transplantation. <i>Transplantation Proceedings</i> , 2018, 50, 2317-2319.	0.6	0
42	VI documento de consenso de la sociedad espa�ola de trasplante hep�tico (SETH). <i>Gastroenterolog�a Y Hepatolog�a</i> , 2018, 41, 406-421.	0.5	9
43	VI consensus document by the Spanish Liver Transplantation Society. <i>Gastroenterolog�a Y Hepatolog�a (English Edition)</i> , 2018, 41, 406-421.	0.1	0
44	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. <i>Journal of Hepatology</i> , 2018, 69, 1250-1259.	3.7	152
45	VI documento de consenso de la sociedad espa�ola de trasplante hep�tico (SETH). <i>Cirug�a Espa�ola</i> , 2018, 96, 326-341.	0.2	4
46	Mesenchymal stromal cells for immunomodulatory cell therapy in liver transplantation: One step at a time. <i>Journal of Hepatology</i> , 2017, 67, 7-9.	3.7	5
47	Increased risk of portal vein thrombosis in patients with autoimmune hepatitis on the liver transplantation waiting list. <i>Clinical Transplantation</i> , 2017, 31, e13001.	1.6	7
48	An objective definition for clinical suspicion of T-cell-mediated rejection after liver transplantation. <i>Clinical Transplantation</i> , 2017, 31, e13005.	1.6	13
49	Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. <i>Journal of Hepatology</i> , 2017, 67, 1168-1176.	3.7	96
50	Delta-MELD and survival after liver transplantation: the slope matters. <i>Liver International</i> , 2016, 36, 949-951.	3.9	1
51	Development of multiorgan calciphylaxis during teriparatide, vitamin D, and calcium treatment. <i>Osteoporosis International</i> , 2016, 27, 2631-2634.	3.1	9
52	Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 298-304.	2.4	32
53	Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. <i>Liver Transplantation</i> , 2015, 21, 1347-1354.	2.4	48
54	Noninvasive assessment of liver function. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 199-208.	2.3	30

#	ARTICLE	IF	CITATIONS
55	Candida norvegensis fungemia in a liver transplant recipient. Revista Iberoamericana De Micologia, 2015, 32, 115-117.	0.9	9
56	Epidemiology, clinical characteristics, and outcome of invasive aspergillosis in renal transplant patients. Transplant Infectious Disease, 2014, 16, 951-957.	1.7	31
57	Stage of cirrhosis predicts the risk of liver-related death in patients with low model for End-Stage liver disease scores and cirrhosis awaiting liver transplantation. Liver Transplantation, 2014, 20, 1193-1201.	2.4	41
58	Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: Results from a multicenter Spanish study. Journal of Hepatology, 2014, 61, 1020-1028.	3.7	90
59	Bone Disease in Patients Awaiting Liver Transplantation. Has the Situation Improved in the Last Two Decades?. Calcified Tissue International, 2013, 93, 571-576.	3.1	19
60	Chrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology, 2010, 51, 974-985.	7.3	141
61	Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology, 2010, 51, 1567-1576.	7.3	117
62	Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. Liver International, 2010, 30, 31-41.	3.9	44
63	Combined liver-kidney transplantation in patients with cirrhosis and chronic kidney disease. Nephrology Dialysis Transplantation, 2010, 25, 2356-2363.	0.7	15
64	Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition. Gastroenterology, 2010, 138, 347-359.	1.3	195
65	Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. American Journal of Physiology - Renal Physiology, 2009, 297, G726-G734.	3.4	110
66	Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. Digestive and Liver Disease, 2009, 41, e4-e7.	0.9	14
67	Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis. Gastroenterology, 2009, 136, 1639-1650.	1.3	197
68	Angiotensin II Activates I β B Kinase Phosphorylation of RelA at Ser536 to Promote Myofibroblast Survival and Liver Fibrosis. Gastroenterology, 2009, 136, 2334-2344.e1.	1.3	117
69	Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. American Journal of Physiology - Renal Physiology, 2009, 296, G147-G156.	3.4	79
70	A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis. American Journal of Gastroenterology, 2008, 103, 2747-2756.	0.4	268
71	Hepatic Expression of Candidate Genes in Patients With Alcoholic Hepatitis: Correlation With Disease Severity. Gastroenterology, 2007, 132, 687-697.	1.3	108
72	Bradykinin Attenuates Hepatocellular Damage and Fibrosis in Rats With Chronic Liver Injury. Gastroenterology, 2007, 133, 2019-2028.	1.3	41

#	ARTICLE	IF	CITATIONS
73	Resistin as an Intrahepatic Cytokine. American Journal of Pathology, 2006, 169, 2042-2053.	3.8	142
74	Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. American Journal of Physiology - Renal Physiology, 2006, 291, G877-G884.	3.4	54
75	Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. Journal of Hepatology, 2005, 43, 272-282.	3.7	78
76	Large spontaneous splenorenal shunt as a cause of chronic hepatic encephalopathy. Journal of Hepatology, 2004, 40, 868.	3.7	7
77	Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology, 2003, 125, 117-125.	1.3	317
78	Use of albumin in the management of patients with decompensated cirrhosis. Digestive and Liver Disease, 2003, 35, 668-672.	0.9	8
79	Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. Journal of Hepatology, 2003, 38, 69-89.	3.7	223
80	Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology, 2002, 35, 140-148.	7.3	788
81	Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: Regulation by cytokines and bacterial lipopolysaccharide. Hepatology, 1999, 29, 1057-1063.	7.3	68
82	Nitric oxide production and inducible nitric oxide synthase expression in peritoneal macrophages of cirrhotic patients. Hepatology, 1999, 30, 670-676.	7.3	41